{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:09:00Z","timestamp":1794665340465,"version":"4.9.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T00:00:00Z","timestamp":1731196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA008748"],"award-info":[{"award-number":["P30-CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Urology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ajur.2024.09.003","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T03:44:56Z","timestamp":1731555896000},"page":"422-433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prostate cancer screening"],"prefix":"10.1016","volume":"12","author":[{"given":"Rodrigo","family":"Espa\u00f1a Navarro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Antonio","family":"Gonz\u00e1lez-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Daniel","family":"Subiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora","family":"P\u00e9rez-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid V.","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajur.2024.09.003_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2024.09.003_bib2","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","article-title":"Epidemiology and prevention of prostate cancer","volume":"4","author":"Gandaglia","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ajur.2024.09.003_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 update on prostate cancer epidemiology and risk factors\u2014a systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"issue":"2 Pt 1","key":"10.1016\/j.ajur.2024.09.003_bib4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0022-5347(17)35487-3","article-title":"The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients","volume":"150","author":"Sakr","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2024.09.003_bib5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.eururo.2015.10.029","article-title":"Clinical utility of quantitative Gleason grading in prostate biopsies and prostatectomy specimens","volume":"69","author":"Sauter","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2024.09.003_bib6","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajur.2024.09.003_bib7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.euo.2023.12.005","article-title":"Comparing the performance of digital rectal examination and prostate-specific antigen as a screening test for prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Matsukawa","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ajur.2024.09.003_bib8","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3390\/jpm13121677","article-title":"Navigating through the controversies and emerging paradigms in early detection of prostate cancer: bridging the gap from classic RCTs to modern population-based pilot programs","volume":"13","author":"G\u00f3mez Rivas","year":"2023","journal-title":"J Personalized Med"},{"key":"10.1016\/j.ajur.2024.09.003_bib9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajur.2024.09.003_bib10","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300018","article-title":"Patient-reported outcomes 12 years after localized prostate cancer treatment","volume":"2","author":"Donovan","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ajur.2024.09.003_bib11","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.21037\/tau-20-1370","article-title":"Active surveillance for prostate cancer","volume":"10","author":"Shill","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.ajur.2024.09.003_bib12","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJMcp2209151","article-title":"Screening for prostate cancer","volume":"388","author":"Pinsky","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajur.2024.09.003_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1464-410X.2007.07138.x","article-title":"The discovery of prostate-specific antigen","volume":"101","author":"Rao","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.ajur.2024.09.003_bib14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1089\/dna.1987.6.429","article-title":"Primary structure of a human glandular kallikrein gene","volume":"6","author":"Schedlich","year":"1987","journal-title":"DNA"},{"key":"10.1016\/j.ajur.2024.09.003_bib15","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1056\/NEJM198710083171501","article-title":"Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate","volume":"317","author":"Stamey","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajur.2024.09.003_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c4521","article-title":"Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study","volume":"341","author":"Vickers","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.ajur.2024.09.003_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2024.09.003_bib18","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMsb2000250","article-title":"Reconsidering the trade-offs of prostate cancer screening","volume":"382","author":"Shoag","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajur.2024.09.003_bib19","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/JU.0000000000002696","article-title":"Results from 22 years of follow-up in the G\u00f6teborg randomized population-based prostate cancer screening trial","volume":"208","author":"Fr\u00e5nlund","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2024.09.003_bib20","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","article-title":"Mortality results from the G\u00f6teborg randomised population-based prostate-cancer screening trial","volume":"11","author":"Hugosson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajur.2024.09.003_bib21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7326\/M16-2586","article-title":"Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials","volume":"167","author":"Tsodikov","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajur.2024.09.003_bib22","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/cncr.30474","article-title":"Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years","volume":"123","author":"Pinsky","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ajur.2024.09.003_bib23","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJMc1515131","article-title":"Reevaluating PSA testing rates in the PLCO trial","volume":"374","author":"Shoag","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajur.2024.09.003_bib24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.2018.0154","article-title":"Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial","volume":"319","author":"Martin","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ajur.2024.09.003_bib25","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2024.4011","article-title":"Prostate-specific antigen screening and 15-year prostate cancer mortality: a secondary analysis of the CAP randomized clinical trial","volume":"331","author":"Martin","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ajur.2024.09.003_bib26","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.jclinepi.2011.06.011","article-title":"Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates","volume":"64","author":"Gulati","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ajur.2024.09.003_bib27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41585-023-00840-0","article-title":"Shared decision-making before prostate cancer screening decisions","volume":"21","author":"Pekala","year":"2024","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ajur.2024.09.003_bib28","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/sj.bjc.6605422","article-title":"Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer","volume":"101","author":"Heijnsdijk","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajur.2024.09.003_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1439","article-title":"Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US","volume":"6","author":"Cooperberg","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ajur.2024.09.003_bib30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41585-022-00638-6","article-title":"Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future","volume":"19","author":"Van Poppel","year":"2022","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ajur.2024.09.003_bib31","article-title":"Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer","volume":"4","author":"Drost","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajur.2024.09.003_bib32","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajur.2024.09.003_bib33","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajur.2024.09.003_bib34","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2024.3841","article-title":"Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial","volume":"331","author":"Auvinen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ajur.2024.09.003_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-059482","article-title":"Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial","volume":"12","author":"Nam","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ajur.2024.09.003_bib36","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate cancer screening with PSA and MRI followed by targeted biopsy only","volume":"387","author":"Hugosson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajur.2024.09.003_bib37","article-title":"Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort study","volume":"2","author":"Moore","year":"2023","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.ajur.2024.09.003_bib38","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2008.08.054","article-title":"Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial","volume":"55","author":"Johansson","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.ajur.2024.09.003_bib39","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMoa1807801","article-title":"Radical prostatectomy or watchful waiting in prostate cancer\u201429-year follow-up","volume":"379","author":"Bill-Axelson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajur.2024.09.003_bib40","first-page":"1133","article-title":"The prostate cancer intervention versus observation trial (PIVOT)","volume":"11","author":"Wilt","year":"1997","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ajur.2024.09.003_bib41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa1615869","article-title":"Follow-up of prostatectomy versus observation for early prostate cancer","volume":"377","author":"Wilt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajur.2024.09.003_bib42","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bju.15739","article-title":"Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)","volume":"130","author":"Lane","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.ajur.2024.09.003_bib43","author":"Cornford"},{"key":"10.1016\/j.ajur.2024.09.003_bib44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JU.0000000000003491","article-title":"Early detection of prostate cancer: AUA\/SUO guideline part I: prostate cancer screening","volume":"210","author":"Wei","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.ajur.2024.09.003_bib45","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: US Preventive Services Task Force recommendation statement","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ajur.2024.09.003_bib46","article-title":"National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology (NCCN Guidelines\u00ae)","author":"Moses","year":"22024","journal-title":"Prostate Cancer Early Detection"},{"key":"10.1016\/j.ajur.2024.09.003_bib48","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/tau.2017.12.21","article-title":"Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome","volume":"7","author":"Pereira-Azevedo","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.ajur.2024.09.003_bib49","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/cncr.25568","article-title":"Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50","volume":"117","author":"Lilja","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ajur.2024.09.003_bib50","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/ijc.33940","article-title":"A randomized trial of risk-adapted screening for prostate cancer in young men\u2014results of the first screening round of the PROBASE trial","volume":"150","author":"Arsov","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajur.2024.09.003_bib51","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ijc.34295","article-title":"Adherence to a risk-adapted screening strategy for prostate cancer: first results of the PROBASE trial","volume":"152","author":"Krilaviciute","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajur.2024.09.003_bib52","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bju.15683","article-title":"Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study","volume":"130","author":"Rannikko","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.ajur.2024.09.003_bib53","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/bju.15535","article-title":"The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening","volume":"129","author":"Benafif","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.ajur.2024.09.003_bib54","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2023.08.002","article-title":"Early detection of prostate cancer in the European Union: combining forces with PRAISE-U","volume":"84","author":"Van Poppel","year":"2023","journal-title":"Eur Urol"}],"container-title":["Asian Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214388224001279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214388224001279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:27:08Z","timestamp":1768955228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214388224001279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2214388224001279"],"URL":"https:\/\/doi.org\/10.1016\/j.ajur.2024.09.003","relation":{},"ISSN":["2214-3882"],"issn-type":[{"value":"2214-3882","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate cancer screening","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajur.2024.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Editorial Office of Asian Journal of Urology. Publishing services by Elsevier B.V\u00e9","name":"copyright","label":"Copyright"}]}}